Ocean Biomedical (OCEA) shares were up 88% premarket Wednesday after the company said that its co-founder, Jonathan Kurtis, and his research team have received additional funding from the National Institutes of Health to further their malaria vaccine research.
The company said that recent US Food and Drug Administration guidance on lipid-encapsulated vaccines could provide an expedited development pathway for their approach.
Ocean Biomedical said it could potentially begin human trials as early as Q4.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.